The study compared biosimilar approval and launch dates in Japan, the USA and the EU. It also measured patient access time, the interval from approval to first commercial launch. Data came from public PMDA, FDA and EMA records, supplemented by company press releases. Median patient access time was 6 months in Japan, 15 months in the USA and 17 months in the EU. Japan still approved biosimilars later, yet its first launches were often as early as or earlier than elsewhere. Launch marks only the earliest point of access, not later uptake in clinical practice.
Why it is interesting: Approval dates alone can misstate when patients can actually obtain a biosimilar. The authors argue that assessing access also requires looking at post-approval steps such as market entry, pricing and reimbursement.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.